<code id="mbjo2"></code>
      <thead id="mbjo2"></thead>
      <object id="mbjo2"><video id="mbjo2"></video></object>
    1. <big id="mbjo2"></big>

      <code id="mbjo2"><nobr id="mbjo2"><sub id="mbjo2"></sub></nobr></code><th id="mbjo2"><option id="mbjo2"></option></th>
      Skip to main content

      Insights on Pharmaceuticals & Medical Products


      Understanding the opportunity in Japan’s biosimilar market

      – Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial incentives, and commercial model will be keys to success.

      Infographic: Europe’s potential for biotech innovation

      – Europe has world-class universities, research institutions, medical centers, and hospitals that provide a strong base for sourcing... and developing scientific innovation. However, this strength does not yet translate into patents for new medicines, as Europe trails both China and the United States in that area. Increased investment in biotech may hold the key to helping grow Europe’s share of new drugs. Europe’s biotechs currently receive only 20 percent of the funding their US counterparts do. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”

      Infographic: Europe’s biotech hot spots

      – Europe has a complex biotech landscape, with hundreds of companies, multiple paths to innovation and financing, and marked differences... among countries. To see through the complexity, we grouped approximately 1,000 European biotech companies into eight clusters based on country, modality, and therapeutic area. We identified biotech hot spots as well as trends and possible directions for the region. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”

      Biotech in Europe: A strong foundation for growth and innovation

      – European companies have an opportunity to play a stronger role in the industry by focusing on three factors.

      Unlocking market access for gene therapies in the United States

      – Gene therapy holds great promise for treating a variety of diseases, but without changes, today’s payment system could limit... the number of patients who benefit.

      The hidden value of improved capital-expenditure management in pharma

      – Pharmaceutical companies can reap huge rewards from the hundreds of smaller projects they manage, not just from the occasional... big one. Thinking about value, not just costs, is key.

      Designing an agile transformation in pharma R&D

      – Pharmaceutical companies are increasingly turning to the concept of agility to help them transform their R&D functions.

      Piloting a biotech leader to greater growth

      – Growth in a dynamic biotechnology industry requires empowering teams, making real-time adjustments, and shifting the mind-set... to accelerate toward the end goal.

      A vision for medical affairs in 2025

      – Four core areas of medical-affairs activity combine to maximize patient experiences and outcomes.

      Special Collection

      Spotlight on Japan

      As the world’s second-largest pharma and medtech market, Japan has historically been an innovation center for the industry. But amid an evolving healthcare landscape, this collection of articles and interviews looks at what opportunities and challenges executives at life-sciences companies need to address.

      Want to learn more about how we help clients in Pharmaceuticals & Medical Products?

      More insights


      An engineering approach to derisking R&D for novel drug modalities

      – Borrowing from the field of engineering, applying a “failure modes analysis” can quickly take some unnecessary risk... out of a development program for innovative modalities.

      Infographic: European biotech financing is maturing, but the gap with the United States keeps growing

      – How much financing is needed to encourage growth in Europe’s biotech sector? The analysis in our latest report, “ href="/industries/pharmaceuticals-and-medical-products/our-insights/biotech-in-europe-a-strong-foundation-for-growth-and-innovation">Biotech in Europe: A strong foundation for growth and innovation,” shows that investment in European biotechs is increasing. In late-stage financing, however, Europe lags behind the United States by a large (and still growing) margin—the US sector receives almost five times as much private funding as its European counterpart does. But overall, European biotechs have been good value for investors, and financing is maturing.

      Infographic: Building the European biotech sector with world-class talent

      – What makes European biotech attractive? Talent is one reason. Europe ranks high in the level of innovation and the quality of... R&D talent, particularly for research, and the amount of available talent in drug development is increasing. For rare diseases and oncology, however, experienced people are considered to be in short supply. And while the challenges of attracting and retaining biotech talent (as well as talent for business development) are not unique to Europe, these will continue to be important for biotech’s growth in this market. Read more in “Biotech in Europe: A strong foundation for growth and innovation.”

      Agile: The new active ingredient in pharma development

      – Roche’s Frank Duff and Malte Schutz explain how trust, a faster pace, and evolutionary design have transformed their highly... technical (and highly regulated) work.

      Women in the healthcare industry

      – To see how the healthcare sector stacks up on gender equality, we look at employee experiences, policies, and the effectiveness... of industry programs intended to promote diversity and inclusion.

      Solutions and services in medical devices: White space or white elephants?

      – Medical-device players are venturing into adjacent value pools through solutions and services. What do they require to capitalize... on the opportunity and deliver on their profitable growth aspirations?

      Biopharma in China: Insights into a market at a crossroads

      – Biopharma in China is poised for change that will transform commercial and operating models, and require a step change in capabilities.

      Private equity opportunities in healthcare tech

      – Although private equity firms have been hesitant to invest in healthcare tech, they have reason to invest in promising targets... now.

      How much is your company worth to its customers?

      – Established companies with long histories of performance, increasingly face new competitors with no track record and lower prices.... What’s the value of experience?

      Refueling the innovation engine in vaccines

      – Vaccine development has slowed over the past five years, but changes to investment strategies and a shift in focus to more technical... and complex vaccines could renew the innovation engine.

      What’s next for biosimilars in emerging markets?

      – Affordable biologic therapies could help expand patients’ access to treatment in the developing world. Here’s what... pharma companies must know to unlock the potential.
      Sorry, we couldn't find any results. Try removing some filters.

      Connect with our Pharmaceuticals & Medical Products Practice